Anton
After relapsed B-ALL stopped responding to chemotherapy in Russia, Anton accessed CD19 CAR-T cell therapy at Lu Daopei Hospital in Beijing and entered complete remission.
Why the Family Contacted CancerFax
When a young patient with relapsed leukaemia is running out of local options, families face a series of difficult questions very quickly, often in a language and medical system they do not know. This is where structured navigation support matters most.
Many hospitals mention CAR-T, but few have the programme depth and case volume needed for relapsed, refractory leukaemia. Identifying the right centre takes specialist knowledge.
CAR-T eligibility depends on disease type, prior treatment, and overall condition. Understanding whether the case fit required medical documents to be reviewed properly.
Documentation, translation, visas, hospital communication, and logistics all had to come together, in a country the family did not know.
"We did not know where to start, or who to trust. We just knew we could not stop looking." β placeholder quote β replace with a real family quote if available.β Anton's family
How CancerFax Helped
CancerFax worked as the navigator between Anton's family and the specialist centre. The role was not to treat or advise clinically, but to make a complex, cross-border treatment path organised and understandable.
Anton's diagnosis reports, bone marrow findings, and treatment history were compiled into a structured file so the specialist team could review the case quickly and accurately.
CancerFax identified Lu Daopei Hospital in Beijing, a centre with deep haematology and CAR-T experience, as an appropriate match for Anton's relapsed B-ALL.
Medical records were translated and communication between the family and the hospital team was managed throughout the evaluation and treatment process.
Visa documentation, travel, and accommodation for Anton and his accompanying family member were coordinated for the stay in Beijing.
Anton's Treatment Journey
Key steps from diagnosis to treatment and beyond.
Anton was diagnosed with B-cell acute lymphoblastic leukaemia and began intensive chemotherapy with his local care team.
The leukaemia returned and proved difficult to clear with further chemotherapy. The case was now relapsed and refractory, and conventional options at home were running low.
The family reached out to CancerFax. Anton's medical records were reviewed and organised, and CD19 CAR-T cell therapy at a specialist centre was identified as a possible path worth exploring.
Anton travelled to Lu Daopei Hospital in Beijing, where the haematology team carried out a full evaluation to confirm his suitability for CAR-T therapy.
After preparation, Anton received CD19 CAR-T cell therapy. He was monitored closely by the hospital team during the treatment and recovery period.
Following treatment, Anton entered complete remission. He continues under follow-up monitoring with the treating team.
Every patient's treatment plan is individual. The pathway above describes this specific case β not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.
Where Anton Is Today
Anton is currently in complete remission following his CAR-T treatment at Lu Daopei Hospital. After a difficult period of relapsed disease, the response gave him and his family something they had been waiting a long time for.
As with all patients treated for relapsed leukaemia, his progress is followed through regular monitoring. Ongoing follow-up remains an important part of his care, and the focus now is on recovery and staying well.
β"For the first time in a long time, we could think about the future again." β placeholder quote β replace with a real patient or family quote if available.ββ Anton's family
What Other Families Can Learn
Anton's journey offers a few practical takeaways for families facing relapsed or hard-to-treat blood cancers.
When chemotherapy has stopped working in relapsed leukaemia, specialist review can reveal advanced options, such as CAR-T, that were not visible locally.
CAR-T therapy has specific eligibility criteria. Having medical records reviewed early helps families understand whether the patient is a realistic candidate.
Exploring advanced options while the patient is still well enough to travel and undergo treatment can make an important difference.
Records, translation, hospital communication, and travel can be overwhelming. Coordinated support removes those barriers so the family can focus on the patient.
Related on CancerFax
Frequently Asked Questions
This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Need Help Understanding the Next Step?
If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.
Β© CancerFax Β· Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.